ExpreS2ion Biotech Holding AB (publ) announced that additional positive results for the ABNCoV2 vaccine, that is being developed as a universal booster vaccine, has been reported from the Phase II clinical trial conducted by Bavarian Nordic. The new study data demonstrates a significant boost to the neutralizing antibodies against the Omicron variant in the majority of subjects with a fold increase in the same range as previously reported for the original Wuhan SARS-CoV2 variant. Bavarian Nordic continues to plan for rapid initiation of a Phase III study.

Bavarian Nordic announces that data from subjects, who were previously vaccinated with approved mRNA or adenoviral vaccines, demonstrated that vaccination with ABNCoV2 induced a significant boost to the neutralizing antibodies against the Omicron variant in the majority of subjects with a fold increase in the same range as previously reported for the original Wuhan SARS-CoV2 variant. While the neutralizing antibody titers against Omicron were the lowest when compared to all other variants previously reported (Wuhan, Alpha, Beta and Delta) they were boosted to levels associated with a high level of protection across both dose groups, 50µg and 100µg.